This product is a medium-acting sulfonamide. It has antibacterial effects on non-enzyme-producing Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Escherichia coli, Klebsiella, Salmonella, Shigella and other Enterobacteriaceae, gonococci, meningococci, Haemophilus influenzae. In addition, it also has antimicrobial activity against Chlamydia trachomatis, Nocardia asteroides, Plasmodium and Toxoplasma in vitro. The antibacterial activity of this product is the same as that of sulfamethoxazole. However, in recent years, bacterial resistance to this product has increased, especially Streptococcus, Neisseria and Enterobacteriaceae. Sulfonamides are broad-spectrum antibacterial agents. This product is similar in structure to para-aminobenzoic acid (PABA), and can compete with PABA on dihydrofolate synthase in bacteria, thereby preventing PABA from being used as a raw material to synthesize folic acid required by bacteria, and reducing the amount of metabolically active tetrahydrofolate, which is an essential substance for bacteria to synthesize purine, thymidine and deoxyribonucleic acid (DNA), thereby inhibiting the growth and reproduction of bacteria.

This product is a carbonic anhydrase inhibitor, which can inhibit the production of aqueous humor and reduce intraocular pressure. The ease of aqueous humor outflow does not change. Acetazolamide can inhibit the activity of carbonic anhydrase in the ciliary epithelium, thereby reducing the production of aqueous humor (50% to 60%) and lowering intraocular pressure.

This product is a carbonic anhydrase inhibitor, which can inhibit the production of aqueous humor and reduce intraocular pressure. The ease of aqueous humor outflow does not change. Acetazolamide can inhibit the activity of carbonic anhydrase in the ciliary epithelium, thereby reducing the production of aqueous humor (50% to 60%) and lowering intraocular pressure.

1. It can simultaneously relax the coronary arteries in the normal blood supply area and the ischemic area, antagonize spontaneous or ergonovine-induced coronary artery spasm, increase the delivery of myocardial oxygen to patients with coronary artery spasm, and relieve and prevent coronary artery spasm. 2. It can inhibit myocardial contraction, reduce myocardial metabolism, and reduce myocardial oxygen consumption. 3. It can relax peripheral resistance vessels, reduce peripheral resistance, and can reduce systolic and diastolic blood pressure, reducing cardiac afterload. 4. It can delay the sinus node function and atrioventricular conduction of isolated hearts; electrophysiological studies on whole animals and humans have not found that this product has the effect of delaying atrioventricular conduction, prolonging the recovery time of the sinus node, and slowing down the sinus node rate.